Byondis Will Present ADC Technology at World ADC
The company will detail its steric masking platform and preclinical oncology findings in San Diego this October.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize patient safety over rapid development of new cancer drugs?
Byondis B.V. will present technical data on its ByonGuard steric masking technology and lead ADC candidate BYON14156 at the World ADC conference, scheduled for October 12-15, 2026. This development remains in the research-stage, with clinical trials anticipated for 2027.
Why it matters
The company aims to address payload resistance and off-tumor toxicity in cancer treatment through modular, integrated development. Its proprietary platform represents a shift toward more precise drug delivery in oncology, with current results drawn from preclinical models.
Byondis leverages over 20 years of ADC expertise, utilizing a first-in-class antifolate payload combined with its ByonGuard steric masking technology. The approach is designed to improve therapeutic windows compared to standard ADCs by minimizing off-tumor toxicity.
The players
Byondis B.V.
A Netherlands-based biotechnology company specializing in the end-to-end development of Antibody-Drug Conjugates.
Christoph Korpus
The Chief Executive Officer of Byondis, appointed in April 2026 to lead the company's research-to-clinical pipeline.
Wim Dokter
A presenter representing the Byondis research team at the World ADC conference.
The details
Byondis utilizes Antibody-Drug Conjugates (ADCs) — targeted molecules that use antibodies to deliver toxic anti-cancer drugs directly to tumor cells. ByonGuard, the company's steric masking technology, hides the payload from the immune system while the antibody is in circulation to prevent early release. This integrated approach combines discovery and manufacturing to enable the development of agents like BYON14156, which targets an antigen expressed across multiple tumor types.
Timeline
October 12, 2026: Byondis presents on ByonGuard technology at 10:30am PDT.
October 14, 2026: Wim Dokter presents on BYON14156 development at 11:00am PDT.
2027: Expected clinical trial initiation for BYON14156.
The Tech Race
Byondis is positioning its ByonGuard platform within a crowded landscape of ADC developers competing to overcome systemic toxicity. The upcoming presentation benchmarks the company against established industry leaders currently moving to clinical-stage testing of novel antifolate payloads.
The development of BYON14156 will not affect current oncology workflows, as the candidate remains in preclinical stages. Patients and clinicians should look for updates following the 2027 clinical trial initiation to assess potential therapeutic impacts.
The takeaway
Byondis is leveraging two decades of institutional expertise to refine ADC delivery via its steric masking platform. Readers should monitor the 2027 clinical trial launch for data confirming if preclinical toxicity profiles hold in human cohorts.
Further reading
For broader trends in drug delivery platforms, see our Biotech section.
Live Poll
Do you trust pharmaceutical companies to prioritize patient safety over rapid development of new cancer drugs?
